Literature DB >> 16162103

Immunosuppressive effects of surgery assessed by flow cytometry in nonhuman primates after nephrectomy.

Mario Stalder1, Tudor Bîrsan, Bernard Hausen, Dominic C Borie, Randall E Morris.   

Abstract

Despite previous studies suggesting that surgery cause immune suppression, the underlying biologic mechanisms have not been studied using advanced immune function assays. Unilateral nephrectomy was performed in nonhuman primates. Blood was collected before surgery and at different time-points through 14 days after surgery. Lymphocyte proliferation (expression of proliferating cell nuclear antigen in cells in S/G(2)M-phase), production of intracellular cytokines [interleukin (IL)-2, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha] and expression of surface-activation antigens (CD25, CD71) on T-lymphocytes were assessed in whole blood using flow cytometry. Results were compared with nonoperated control animals. The procedure caused a decrease of 25% in absolute lymphocyte count on postoperative day 3. Inhibition of lymphocyte proliferation was maximal on postoperative day 1 (55% normalized to preoperative values) and was detectable until postoperative day 7, when it was 25%. Expression of T-cell activation antigens was decreased during the first postoperative week with a maximum on postoperative day 1 for CD71 (29%) and on postoperative day 3 for CD25 (49%). Intracellular production of cytokines by T cells was decreased only on postoperative day 1 (50% for IL-2, 29% for IFN-gamma and 22% for TNF-alpha). Immune functions returned to presurgery values by day 14. A major surgical procedure severely inhibits lymphocyte proliferation and various T-cell functions up to 1 week postoperatively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162103     DOI: 10.1111/j.1432-2277.2005.00119.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

Review 1.  Effect of surgical resection of metastatic disease on immune tolerance to cancer. How a systemic disease could be controlled by a local therapy.

Authors:  H D González; J Figueras
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

2.  Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.

Authors:  Yue Yang; Nikolas L Jorstad; Christine Shiao; Makenzie K Cherne; Shawn B Khademi; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Exp Mol Pathol       Date:  2013-04-06       Impact factor: 3.362

3.  Irradiation of donor mononuclear cells for treatment of chemorefractory metastatic solid cancers: a community-based immune transplant pilot study.

Authors:  John T Reynolds; John M Watkins; Tarek A Dufan; Shrikant S Kubsad
Journal:  Cancer Res Treat       Date:  2012-06-30       Impact factor: 4.679

4.  Early versus delayed initiation of adjuvant treatment for pancreatic cancer.

Authors:  Hyoung Woo Kim; Jong-Chan Lee; Jongchan Lee; Jin Won Kim; Jaihwan Kim; Jin-Hyeok Hwang
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

5.  Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study.

Authors:  Peng Gao; Xuan-Zhang Huang; Yong-Xi Song; Jing-Xu Sun; Xiao-Wan Chen; Yu Sun; Yu-Meng Jiang; Zhen-Ning Wang
Journal:  BMC Cancer       Date:  2018-03-01       Impact factor: 4.430

6.  Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia.

Authors:  Ana B Sanz; Maria Dolores Sanchez-Niño; Maria Concepcion Izquierdo; Aniela Jakubowski; Pilar Justo; Luis M Blanco-Colio; Marta Ruiz-Ortega; Jesús Egido; Alberto Ortiz
Journal:  J Cell Mol Med       Date:  2009-05-01       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.